Memantine augmentation for refractory obsessive–compulsive disorder

Glutamatergic hyperactivity hypothesis in obsessive–compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N-methyl- d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive–compulsive disorder treated with an augmentation of memantine at...

Full description

Saved in:
Bibliographic Details
Published in:Progress in neuro-psychopharmacology & biological psychiatry Vol. 30; no. 6; pp. 1173 - 1175
Main Authors: Pasquini, Massimo, Biondi, Massimo
Format: Journal Article
Language:English
Published: Amsterdam Elsevier Inc 30.08.2006
Elsevier
Subjects:
Adult
Adult and adolescent clinical studies
Anxiety disorders. Neuroses
Biological and medical sciences
Drug Resistance
Drug Therapy, Combination
Excitatory Amino Acid Antagonists - therapeutic use
Female
Glutamatergic transmission
Humans
Male
Medical sciences
Memantine
Memantine - therapeutic use
Memory for actions
Middle Aged
Neuropharmacology
Obsessive-Compulsive Disorder - drug therapy
Obsessive-Compulsive Disorder - psychology
Obsessive-compulsive disorders
Obsessive–compulsive disorder
Pharmacology. Drug treatments
Psychiatric Status Rating Scales
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Serotonin Uptake Inhibitors - therapeutic use
Obsessive–compulsive disorder
Memantine
Glutamatergic transmission
Memory for actions
Obsessive compulsive disorder
Memory
Anxiety disorder
Glutamate receptor
Antialzheimer agent
Antiparkinson agent
Amantadine dérivatives
Obsessive-compulsive disorder
Antagonist
NMDA receptor
ISSN:0278-5846, 1878-4216
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glutamatergic hyperactivity hypothesis in obsessive–compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N-methyl- d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive–compulsive disorder treated with an augmentation of memantine at 15 mg/day. The first case did not benefit from such treatment, while the second showed immediate and substantial improvement. Contrasting results, reflecting different subtypes of OCD, are discussed. We hypothesized that in certain OCD subtypes an agent that enhances memory for actions may promote a reduction in orbitofrontal activation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Case Study-2
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
ISSN:0278-5846
1878-4216
DOI:10.1016/j.pnpbp.2006.04.013